Telix Pharmaceuticals announces launch of proposed U.S. IPO

Telix Pharmaceuticals announces the launch of its initial public offering in the United States of 17,000,000 American Depositary Shares, each representing one ordinary share in Telix. The target size of the Offering is $200 million in gross proceeds. In addition, Telix expects to grant the Underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs sold in the Offering at the initial public offering price, less underwriting discounts and commissions. All ADSs to be issued in the Offering will be offered by Telix. Jefferies, Morgan Stanley, Truist Securities and William Blair are acting as joint book-running managers for the Offering. Telix has applied to list its ADSs on the Nasdaq Global Market under the ticker symbol “TLX”. Telix’s ordinary shares are listed, and upon the completing of the Offering, will continue to trade on the Australian Securities Exchange under the symbol “TLX”.